130 related articles for article (PubMed ID: 26554440)
1. AMPD1 polymorphism and response to regadenoson.
Saab R; Zouk AN; Mastouri R; Skaar TC; Philips S; Kreutz RP
Pharmacogenomics; 2015 Nov; 16(16):1807-15. PubMed ID: 26554440
[TBL] [Abstract][Full Text] [Related]
2. Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
Posch MI; Kay MD; Harhash AA; Huang JJ; Krupinski EA; Abidov A; McMillan NA; Kuo PH
J Nucl Med Technol; 2020 Mar; 48(1):73-76. PubMed ID: 31604901
[TBL] [Abstract][Full Text] [Related]
3. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
[TBL] [Abstract][Full Text] [Related]
4. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
[TBL] [Abstract][Full Text] [Related]
5. Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson.
Berlacher M; Mastouri R; Philips S; Skaar TC; Kreutz RP
Pharmacogenomics; 2017 Apr; 18(6):523-529. PubMed ID: 28358597
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve.
Arumugham P; Figueredo VM; Patel PB; Morris DL
EuroIntervention; 2013 Feb; 8(10):1166-71. PubMed ID: 23164748
[TBL] [Abstract][Full Text] [Related]
7. Caffeine Consumption and Heart Rate and Blood Pressure Response to Regadenoson.
Bitar A; Mastouri R; Kreutz RP
PLoS One; 2015; 10(6):e0130487. PubMed ID: 26098883
[TBL] [Abstract][Full Text] [Related]
8. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.
Salgado-Garcia C; Jimenez-Heffernan A; Lopez-Martin J; Molina-Mora M; Aroui T; Sanchez de Mora E; Ramos-Font C; Rivera de Los Santos F; Ruiz-Frutos C
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1906-1914. PubMed ID: 28547175
[TBL] [Abstract][Full Text] [Related]
9. Indirect evidence of sympathetic stimulation by regadenoson.
Farris GR; Hage FG; Kumar V; Iskandrian AE
J Nucl Cardiol; 2019 Apr; 26(2):684-687. PubMed ID: 29948894
[No Abstract] [Full Text] [Related]
10. Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging.
Cabrera R; Husain Z; Palani G; Karthikeyan AS; Choudhry Z; Dhanalakota S; Peterson E; Ananthasubramaniam K
J Nucl Cardiol; 2013 Jun; 20(3):336-43; quiz 344-5. PubMed ID: 23430361
[TBL] [Abstract][Full Text] [Related]
11. The heart rate response to regadenoson in patients with atrial fibrillation.
Uzendu AI; Iskandrian A; Hage FG
J Nucl Cardiol; 2018 Jun; 25(3):1012-1016. PubMed ID: 28856613
[No Abstract] [Full Text] [Related]
12. Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing.
Brink HL; Dickerson JA; Stephens JA; Pickworth KK
Pharmacotherapy; 2015 Dec; 35(12):1117-23. PubMed ID: 26684552
[TBL] [Abstract][Full Text] [Related]
13. AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization.
Andreassi MG; Botto N; Laghi-Pasini F; Manfredi S; Ghelarducci B; Farneti A; Solinas M; Biagini A; Picano E
Int J Cardiol; 2005 May; 101(2):191-5. PubMed ID: 15882662
[TBL] [Abstract][Full Text] [Related]
14. Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs.
Zhao G; Serpllion S; Shryock J; Messina E; Xu X; Ochoa M; Belardinelli L; Hintze TH
J Cardiovasc Pharmacol; 2008 Nov; 52(5):467-73. PubMed ID: 19033827
[TBL] [Abstract][Full Text] [Related]
15. Effects of AMPD1 common mutation on the metabolic-chronotropic relationship: Insights from patients with myoadenylate deaminase deficiency.
Rannou F; Scotet V; Marcorelles P; Monnoyer R; Le Maréchal C
PLoS One; 2017; 12(11):e0187266. PubMed ID: 29095874
[TBL] [Abstract][Full Text] [Related]
16. Regadenoson: a new myocardial stress agent.
Al Jaroudi W; Iskandrian AE
J Am Coll Cardiol; 2009 Sep; 54(13):1123-30. PubMed ID: 19761931
[TBL] [Abstract][Full Text] [Related]
17. Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis.
Feng AF; Liu ZH; Zhou SL; Zhao SY; Zhu YX; Wang HX
BMC Cardiovasc Disord; 2017 Jul; 17(1):174. PubMed ID: 28673246
[TBL] [Abstract][Full Text] [Related]
18. Safety of regadenoson for vasodilation in cardiac MRI stress tests.
Bastarrika G; Ezponda A; Baizan AG; Calvo M; Pueyo JC; Gavira JJ; Caballeros M
Radiologia (Engl Ed); 2020; 62(3):213-221. PubMed ID: 31862182
[TBL] [Abstract][Full Text] [Related]
19. Advanced hybrid stress testing: a potential new paradigm combining exercise and pharmacologic stress.
Thomas GS; Hundal HS; Ellestad MH
J Nucl Cardiol; 2012 Oct; 19(5):887-90. PubMed ID: 22926630
[No Abstract] [Full Text] [Related]
20. Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson.
Noel CV; Krishnamurthy R; Moffett B; Krishnamurthy R
Pediatr Radiol; 2017 Mar; 47(3):280-289. PubMed ID: 28035425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
